Science Explorer Interactive view Map
Company · Hangzhou · China

Betta Pharmaceuticals (China)

bettapharma.comROR OpenAlex
Research works
60
▲ 243% vs 2013–17
Citations
440
7.3 per fractional work
Top-10% rate
7.0%
record average 16.5%
Open access
33%
world 28%

Not ranked overall: Betta Pharmaceuticals (China) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.25× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 6.08× its world share, 11 worksBiochemistry, Geneti…Immunology and Microbiology: 2.97× its world share, 1 worksImmunology and Micro…Neuroscience: 0.31× its world share, 0 worksNeuroscienceChemistry: 0.16× its world share, 0 worksChemistryEngineering: 0.24× its world share, 1 worksEngineeringEnvironmental Science: 0.35× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.28× its world share, 0 worksMaterials ScienceMedicine: 2.79× its world share, 18 worksMedicineNursing: 0.34× its world share, 0 worksNursingEconomics, Econometrics and Finance: 1.17× its world share, 1 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 6.1×. Every wedge is a field page.

Which keywords describe research at Betta Pharmaceuticals (China)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Chemotherapy, Targeted Therapy, Clinical Trials, Immunotherapy, Cancer, Cancer Therapy, Treatment Guidelines and ALK Inhibitors.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Chemotherapy5▲ 23×7 topics
  2. Targeted Therapy5▲ 66×4 topics
  3. Clinical Trials4▲ 20×2 topics
  4. Immunotherapy4▲ 16×7 topics
  5. Cancer4▲ 8.6×8 topics
  6. Cancer Therapy4▲ 20×9 topics
  7. ALK Inhibitors3▲ 144×1 topic
  8. EGFR Mutations3▲ 144×1 topic
  9. Treatment Guidelines3▲ 42×2 topics
  10. Tumor Microenvironment3▲ 19×6 topics
  11. Metastasis2▲ 22×3 topics
  12. Regulation2▲ 13×2 topics
  13. Cell Proliferation2▲ 74×2 topics
  14. Tumor Targeting2▲ 35×3 topics
  15. Breast Cancer2▲ 22×2 topics
  16. Hippo Pathway2▲ 393×1 topic
  17. YAP/TAZ2▲ 393×1 topic
  18. Cell Death2▲ 21×2 topics
  19. Reactive Oxygen Species2▲ 12×3 topics
  20. Biomarkers2▲ 7.0×2 topics
  21. Gene Therapy2▲ 26×2 topics
  22. Monoclonal Antibody2▲ 86×2 topics
  23. Genomic Profiles1▲ 102×1 topic
  24. Precision Medicine1▲ 9.1×3 topics
  25. Prognostic Factors1▲ 9.9×2 topics
  26. Receptor tyrosine kinases1▲ 117×2 topics
  27. Small-Cell Lung Cancer1▲ 102×1 topic
  28. Angiogenesis1▲ 12×4 topics
  29. BRCA Mutation1▲ 178×1 topic
  30. Glycosylation1▲ 35×2 topics
  31. HER21▲ 132×1 topic
  32. Metastatic1▲ 61×2 topics
  33. PARP Inhibitors1▲ 178×1 topic
  34. Trastuzumab1▲ 83×1 topic
  35. HIF-11▲ 58×1 topic
  36. Warburg Effect1▲ 58×1 topic
  37. Cetuximab1▲ 40×1 topic
  38. KRAS Mutations1▲ 102×1 topic
  39. Molecular Subtypes1▲ 40×2 topics
  40. Radiotherapy1▲ 8.7×3 topics

Which research topics does Betta Pharmaceuticals (China) publish most on?

By volume in 2022–2025: Lung Cancer Treatments and Mutations, Hippo pathway signaling and YAP/TAZ, Lung Cancer Research Studies and HER2/EGFR in Cancer Research.

Lung Cancer Treatments a…3Lung Cancer Treatments and Mutations: 3 fractional worksHippo pathway signaling and YAP/TAZ: 2 fractional worksLung Cancer Research Studies: 1 fractional worksHER2/EGFR in Cancer Research: 1 fractional worksPARP inhibition in cancer therapy: 1 fractional worksCancer, Hypoxia, and Metabolism: 1 fractional worksColorectal Cancer Treatm…1Colorectal Cancer Treatments and Studies: 1 fractional worksMonoclonal and Polyclonal Antibodies Research: 1 fractional worksNanoplatforms for cancer theranostics: 1 fractional worksCancer Research and Trea…1Cancer Research and Treatments: 1 fractional works
Pulmonary and Respiratory MedicineCell BiologyOncologyCancer Research3 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 3 works
  2. 2 Hippo pathway signaling and YAP/TAZ Cell Biology 2 works
  3. 3 Lung Cancer Research Studies Oncology 1 works
  4. 4 HER2/EGFR in Cancer Research Oncology 1 works
  5. 5 PARP inhibition in cancer therapy Oncology 1 works
  6. 6 Cancer, Hypoxia, and Metabolism Cancer Research 1 works
  7. 7 Colorectal Cancer Treatments and Studies Oncology 1 works
  8. 8 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  9. 9 Nanoplatforms for cancer theranostics Biomedical Engineering 1 works
  10. 10 Cancer Research and Treatments Biotechnology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available33.0%not open67.0%

World: 28% of research is openly available.

with international co-authors10.3%domestic only89.7%

World: 19% is written across borders.

How has Betta Pharmaceuticals (China)'s research output changed?

Output in 2018–2022 was 243% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Hangzhou

All research institutions in Hangzhou

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.